Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 3/2018

03.05.2018 | Multiple Myeloma (P Kapoor, Section Editor)

Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney—What We Know and What the Future May Hold

verfasst von: Sandhya Manohar, Samih H. Nasr, Nelson Leung

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

To update and evaluate the current knowledge on pathogenesis and management of light chain cast nephropathy. Light chain cast nephropathy (LCCN) is the leading cause of acute renal failure in patients with multiple myeloma and is currently recognized as a myeloma defining event.

Recent findings

The immunoglobulin free light chain plays an integral role in the pathogenesis of LCCN. The level of free light chain (FLC) in the blood and urine is directly associated with the risk of developing LCCN. Recovery of renal function is related to the speed and degree of the serum FLC reduction. Recently, two randomized trials using high cutoff dialyzer for the removal of serum FLC produced different results in terms of renal recovery.

Summary

FLC plays a key role in the development and resolution of LCCN. Future therapies will aim to rapidly reduce its concentration or interrupt its interaction with Tamm-Horsfall protein.
Literatur
1.
Zurück zum Zitat Steensma DP, Kyle RA. A history of the kidney in plasma cell disorders. Contrib Nephrol. 2007;153:5–24.CrossRefPubMed Steensma DP, Kyle RA. A history of the kidney in plasma cell disorders. Contrib Nephrol. 2007;153:5–24.CrossRefPubMed
2.
Zurück zum Zitat Thannhauser S, Krauss E. Uber eine degenerative Erkrankung der Harnkanalchen (Nephrose) bei Bence-Jones'scher Albuminurie mit Nierenschwund (kleine, glatte, weisse Niere). Dtsch Arch Klin Med. 1920;133:183–92. Thannhauser S, Krauss E. Uber eine degenerative Erkrankung der Harnkanalchen (Nephrose) bei Bence-Jones'scher Albuminurie mit Nierenschwund (kleine, glatte, weisse Niere). Dtsch Arch Klin Med. 1920;133:183–92.
3.
Zurück zum Zitat Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292–5.CrossRefPubMed Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292–5.CrossRefPubMed
4.
Zurück zum Zitat Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.CrossRefPubMed Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.CrossRefPubMed
5.
Zurück zum Zitat Vos JM, Gustine J, Rennke HG, Hunter Z, Manning RJ, Dubeau TE, et al. Renal disease related to Waldenstrom macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016;175(4):623–30.CrossRefPubMed Vos JM, Gustine J, Rennke HG, Hunter Z, Manning RJ, Dubeau TE, et al. Renal disease related to Waldenstrom macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016;175(4):623–30.CrossRefPubMed
6.
Zurück zum Zitat Burke JR Jr, Flis R, Lasker N, Simenhoff M. Malignant lymphoma with “myeloma kidney” acute renal failure. Am J Med. 1976;60(7):1055–60.CrossRefPubMed Burke JR Jr, Flis R, Lasker N, Simenhoff M. Malignant lymphoma with “myeloma kidney” acute renal failure. Am J Med. 1976;60(7):1055–60.CrossRefPubMed
7.
Zurück zum Zitat Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, et al. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica. 2015;100(9):1180–8.CrossRefPubMedPubMedCentral Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, et al. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica. 2015;100(9):1180–8.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Sanders PW, Herrera GA, Galla JH. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int. 1987;32(6):851–61.CrossRefPubMed Sanders PW, Herrera GA, Galla JH. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int. 1987;32(6):851–61.CrossRefPubMed
9.
Zurück zum Zitat Huang ZQ, Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest. 1997;99(4):732–6.CrossRefPubMedPubMedCentral Huang ZQ, Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest. 1997;99(4):732–6.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Sanders PW. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med. 1994;124(4):484–8.PubMed Sanders PW. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med. 1994;124(4):484–8.PubMed
12.
Zurück zum Zitat Pesce AJ, Clyne DH, Pollak VE, Kant SK, Foulkes EC, Selenke WM. Renal tubular interactions of proteins. Clin Biochem. 1980;13(5):209–15.CrossRefPubMed Pesce AJ, Clyne DH, Pollak VE, Kant SK, Foulkes EC, Selenke WM. Renal tubular interactions of proteins. Clin Biochem. 1980;13(5):209–15.CrossRefPubMed
13.
Zurück zum Zitat Sanders PW, Booker BB, Bishop JB, Cheung HC. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest. 1990;85(2):570–6.CrossRefPubMedPubMedCentral Sanders PW, Booker BB, Bishop JB, Cheung HC. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest. 1990;85(2):570–6.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73(11):1282–8.CrossRefPubMed Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73(11):1282–8.CrossRefPubMed
15.
Zurück zum Zitat Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108(6):2013–9.CrossRefPubMed Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108(6):2013–9.CrossRefPubMed
16.
Zurück zum Zitat Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest. 1972;51(8):2162–74.CrossRefPubMedPubMedCentral Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest. 1972;51(8):2162–74.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18(3):886–95.CrossRefPubMed Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18(3):886–95.CrossRefPubMed
18.
Zurück zum Zitat Ying WZ, Wang PX, Sanders PW. Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis. Am J Pathol. 2012;180(1):41–7.CrossRefPubMedPubMedCentral Ying WZ, Wang PX, Sanders PW. Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis. Am J Pathol. 2012;180(1):41–7.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53(4):207–12.CrossRefPubMed Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53(4):207–12.CrossRefPubMed
20.
Zurück zum Zitat Leboulleux M, Lelongt B, Mougenot B, Touchard G, Makdassi R, Rocca A, et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int. 1995;48(1):72–9.CrossRefPubMed Leboulleux M, Lelongt B, Mougenot B, Touchard G, Makdassi R, Rocca A, et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int. 1995;48(1):72–9.CrossRefPubMed
21.
Zurück zum Zitat Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol. 2012;7(12):1964–8.CrossRefPubMedPubMedCentral Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol. 2012;7(12):1964–8.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281–9.CrossRefPubMed Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281–9.CrossRefPubMed
23.
Zurück zum Zitat Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164–72.PubMed Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164–72.PubMed
24.
Zurück zum Zitat Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(2):230–69.CrossRef Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(2):230–69.CrossRef
25.
Zurück zum Zitat Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195–200.CrossRefPubMed Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195–200.CrossRefPubMed
26.
Zurück zum Zitat Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014;99(1):148–54.CrossRefPubMedPubMedCentral Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014;99(1):148–54.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Ponisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol. 2012;138(8):1405–12.CrossRefPubMed Ponisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol. 2012;138(8):1405–12.CrossRefPubMed
28.
Zurück zum Zitat Ponisch W, Holzvogt B, Plotze M, Andrea M, Bourgeois M, Heyn S, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol. 2014;140(11):1947–56.CrossRefPubMed Ponisch W, Holzvogt B, Plotze M, Andrea M, Bourgeois M, Heyn S, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol. 2014;140(11):1947–56.CrossRefPubMed
29.
Zurück zum Zitat Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92(4):546–9.CrossRefPubMed Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92(4):546–9.CrossRefPubMed
30.
Zurück zum Zitat Bayraktar UD, Warsch S, Pereira D. High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma. Am J Hematol. 2011;86(2):224–7.CrossRefPubMed Bayraktar UD, Warsch S, Pereira D. High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma. Am J Hematol. 2011;86(2):224–7.CrossRefPubMed
31.
Zurück zum Zitat Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22(6):1129–36.CrossRefPubMedPubMedCentral Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22(6):1129–36.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296.CrossRefPubMedPubMedCentral Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143(11):777–84.CrossRefPubMed Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143(11):777–84.CrossRefPubMed
34.
Zurück zum Zitat Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2008;32(12):910–7.CrossRefPubMed Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2008;32(12):910–7.CrossRefPubMed
35.
Zurück zum Zitat •• Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, et al. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. Jama. 2017;318(21):2099–110. Randomized trial using high cutoff dialyzer for the removal of free light chain in patients with light chain cast neprhopathy. CrossRefPubMedPubMedCentral •• Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, et al. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. Jama. 2017;318(21):2099–110. Randomized trial using high cutoff dialyzer for the removal of free light chain in patients with light chain cast neprhopathy. CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Trivedi H, Letter KS. Renal transplantation in lethal disease. Ann Intern Med. 1976;85(1):132–3.CrossRefPubMed Trivedi H, Letter KS. Renal transplantation in lethal disease. Ann Intern Med. 1976;85(1):132–3.CrossRefPubMed
37.
Zurück zum Zitat • Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–400. Potential new therapy for patients with multiple myeloma with t(11;14) abnormality. CrossRefPubMed • Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–400. Potential new therapy for patients with multiple myeloma with t(11;14) abnormality. CrossRefPubMed
Metadaten
Titel
Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney—What We Know and What the Future May Hold
verfasst von
Sandhya Manohar
Samih H. Nasr
Nelson Leung
Publikationsdatum
03.05.2018
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 3/2018
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-018-0451-0

Weitere Artikel der Ausgabe 3/2018

Current Hematologic Malignancy Reports 3/2018 Zur Ausgabe

Health Economics (N Khera, Section Editor)

Frailty in Hematologic Malignancy

Multiple Myeloma (P Kapoor, Section Editor)

How We Manage Patients with Plasmacytomas

Myeloproliferative Neoplasms (B Stein, Section Editor)

Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms

Myeloproliferative Neoplasms (B Stein, Section Editor)

Management of Myelofibrosis-Related Cytopenias

Myeloproliferative Neoplasms (B Stein, Section Editor)

Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.